PDF(Pubmed)
Abstract：
Alcoholic fatty liver disease (FALD) and non-alcoholic fatty liver disease (NAFLD) have similar pathological spectra, both of which are associated with a series of symptoms, including steatosis, inflammation, and fibrosis. These clinical manifestations are caused by hepatic lipid synthesis and metabolism dysregulation and affect human health. Despite having been studied extensively, targeted therapies remain elusive. The Cytochrome P450 (CYP450) family is the most important drug-metabolising enzyme in the body, primarily in the liver. It is responsible for the metabolism of endogenous and exogenous compounds, completing biological transformation. This process is relevant to the occurrence and development of AFLD and NAFLD. In this review, the correlation between CYP450 and liver lipid metabolic diseases is summarised, providing new insights for the treatment of AFLD and NAFLD.
摘要：
酒精性脂肪性肝病(FALD)和非酒精性脂肪性肝病(NAFLD)具有相似的病理谱,两者都与一系列症状有关，包括脂肪变性,炎症,和纤维化。这些临床表现是由肝脏脂质合成和代谢失调引起的，影响人类健康。尽管经过广泛的研究,靶向治疗仍然难以捉摸。细胞色素P450（CYP450）家族是体内最重要的药物代谢酶，主要在肝脏。它负责内源性和外源性化合物的代谢，完成生物转化。这一进程与AFLD和NAFLD的发生和成长有关。在这次审查中,总结了CYP450与肝脏脂质代谢疾病的相关性，为AFLD和NAFLD的治疗提供新的见解。
